Fosun Pharma Proformes Well in Anti-Tumor Sector and Plans to Board on Chinese STAR Market
According to Fosun Parma's quarterly report, due to the outbreak of the epidemic, the company's revenue increased by 11.5% to CNY 6.125 billion in the first quarter of 2020. Among all, Anti-Tumor Business Segment performed exceptionally well with a 53.7% increase year-on-year. Meanwhile, the company continued to increase R&D input, with an investment of CNY 568 million in the first quarter of 2020, accounting for 11.5% of the company's medicine revenue. The company is currently planning to board on the Chinese STAR Market to help boost the R&D of its new drugs.
Source: First Shanghai Group